Current and Emerging Treatments for Metastatic Renal Cell Carcinoma

Carla Cavaliere, Carmine D Aniello, Chiara Della Pepa, Salvatore Pisconti, Massimiliano Berretta, Gaetano Facchini

Research output: Contribution to journalArticle

Abstract

In the last decades the treatment of mRCC, metastatic Renal Cell Carcinoma, has become more and more complex due to the approval of a great number of effective systemic treatments that have significantly improved the prognosis of patients suffering from such disease. An increasing knowledge of the genetic aberrations and the molecular pathways alterations that underlie RCC, has promoted the development of several novel agents, known as target therapies (TTs). Even though TTs are not curative and all patients eventually progressed, an adequate sequencing of these drugs can provide a significant benefit in terms of PFS, Progression Free Survival, and hopefully OS, Overall Survival. To date there are few data about the optimal sequential use of the TTs hence, in clinical practice, the therapeutic strategy is chosen on the basis of the safety profile of the drug, patients medical history and the pivotal trial results, though such studies often exclude patients with poor performance status and/or severe comorbidities that we routinely see in our clinics. This review aims to provide an overview of the systemic therapies for mRCC both in the newly diagnosed patients and in the subsequent lines of treatment, with a special focus on the last advances about TTs and immunotherapy.

Original languageEnglish
JournalCurrent Cancer Drug Targets
DOIs
Publication statusPublished - 2018

Fingerprint

Renal Cell Carcinoma
Therapeutics
Pharmaceutical Preparations
Immunotherapy
Disease-Free Survival
Comorbidity
Molecular Biology
Safety
Survival

Cite this

Current and Emerging Treatments for Metastatic Renal Cell Carcinoma. / Cavaliere, Carla; D Aniello, Carmine; Pepa, Chiara Della; Pisconti, Salvatore; Berretta, Massimiliano; Facchini, Gaetano.

In: Current Cancer Drug Targets, 2018.

Research output: Contribution to journalArticle

Cavaliere, Carla ; D Aniello, Carmine ; Pepa, Chiara Della ; Pisconti, Salvatore ; Berretta, Massimiliano ; Facchini, Gaetano. / Current and Emerging Treatments for Metastatic Renal Cell Carcinoma. In: Current Cancer Drug Targets. 2018.
@article{41d38b39a2644613bfd3a9df151c3a87,
title = "Current and Emerging Treatments for Metastatic Renal Cell Carcinoma",
abstract = "In the last decades the treatment of mRCC, metastatic Renal Cell Carcinoma, has become more and more complex due to the approval of a great number of effective systemic treatments that have significantly improved the prognosis of patients suffering from such disease. An increasing knowledge of the genetic aberrations and the molecular pathways alterations that underlie RCC, has promoted the development of several novel agents, known as target therapies (TTs). Even though TTs are not curative and all patients eventually progressed, an adequate sequencing of these drugs can provide a significant benefit in terms of PFS, Progression Free Survival, and hopefully OS, Overall Survival. To date there are few data about the optimal sequential use of the TTs hence, in clinical practice, the therapeutic strategy is chosen on the basis of the safety profile of the drug, patients medical history and the pivotal trial results, though such studies often exclude patients with poor performance status and/or severe comorbidities that we routinely see in our clinics. This review aims to provide an overview of the systemic therapies for mRCC both in the newly diagnosed patients and in the subsequent lines of treatment, with a special focus on the last advances about TTs and immunotherapy.",
author = "Carla Cavaliere and {D Aniello}, Carmine and Pepa, {Chiara Della} and Salvatore Pisconti and Massimiliano Berretta and Gaetano Facchini",
note = "Copyright{\circledC} Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",
year = "2018",
doi = "10.2174/1568009617666170209094030",
language = "English",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Current and Emerging Treatments for Metastatic Renal Cell Carcinoma

AU - Cavaliere, Carla

AU - D Aniello, Carmine

AU - Pepa, Chiara Della

AU - Pisconti, Salvatore

AU - Berretta, Massimiliano

AU - Facchini, Gaetano

N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

PY - 2018

Y1 - 2018

N2 - In the last decades the treatment of mRCC, metastatic Renal Cell Carcinoma, has become more and more complex due to the approval of a great number of effective systemic treatments that have significantly improved the prognosis of patients suffering from such disease. An increasing knowledge of the genetic aberrations and the molecular pathways alterations that underlie RCC, has promoted the development of several novel agents, known as target therapies (TTs). Even though TTs are not curative and all patients eventually progressed, an adequate sequencing of these drugs can provide a significant benefit in terms of PFS, Progression Free Survival, and hopefully OS, Overall Survival. To date there are few data about the optimal sequential use of the TTs hence, in clinical practice, the therapeutic strategy is chosen on the basis of the safety profile of the drug, patients medical history and the pivotal trial results, though such studies often exclude patients with poor performance status and/or severe comorbidities that we routinely see in our clinics. This review aims to provide an overview of the systemic therapies for mRCC both in the newly diagnosed patients and in the subsequent lines of treatment, with a special focus on the last advances about TTs and immunotherapy.

AB - In the last decades the treatment of mRCC, metastatic Renal Cell Carcinoma, has become more and more complex due to the approval of a great number of effective systemic treatments that have significantly improved the prognosis of patients suffering from such disease. An increasing knowledge of the genetic aberrations and the molecular pathways alterations that underlie RCC, has promoted the development of several novel agents, known as target therapies (TTs). Even though TTs are not curative and all patients eventually progressed, an adequate sequencing of these drugs can provide a significant benefit in terms of PFS, Progression Free Survival, and hopefully OS, Overall Survival. To date there are few data about the optimal sequential use of the TTs hence, in clinical practice, the therapeutic strategy is chosen on the basis of the safety profile of the drug, patients medical history and the pivotal trial results, though such studies often exclude patients with poor performance status and/or severe comorbidities that we routinely see in our clinics. This review aims to provide an overview of the systemic therapies for mRCC both in the newly diagnosed patients and in the subsequent lines of treatment, with a special focus on the last advances about TTs and immunotherapy.

U2 - 10.2174/1568009617666170209094030

DO - 10.2174/1568009617666170209094030

M3 - Article

C2 - 28183256

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

ER -